Total Utang marang Modal Viracta Therapeutics (VIRX)

Viracta Therapeutics - logo grafis emiten VIRX

Viracta Therapeutics (VIRX) develops drugs for viral-induced oncological diseases, demonstrating high resilience to market cycles thanks to its patent portfolio. However, the company faces intense pressure from pharmaceutical industry behemoths. This chart of the separate_debt_total_eq metric is fixed at 0.00. The business currently relies on the completion of final trials for targeted lymphoma treatments, awaiting official approvals for monetization.

Viracta Therapeutics Inc. (VIRX): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 16.02.2025

Rincian metrik lan analitis perusahaan Viracta Therapeutics, Inc. (VIRX)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Viracta Therapeutics Inc.|VIRX - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Viracta Therapeutics|VIRX - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Viracta Therapeutics|VIRX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku viracta.com|VIRX - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Viracta Therapeutics|VIRX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Viracta Therapeutics Inc.|VIRX - Kewajiban utang agregat|Utang marang nilai buku Viracta Therapeutics|VIRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Viracta Therapeutics|Indikator likuiditas cepet viracta.com
- data bathi resik lan rasio valuasi:
VIRX - Bathi resik
Pambiji fundamental perusahaan:Viracta Therapeutics
Produk dadi Viracta Therapeutics Inc.

This indicator measures financial leverage by comparing total liabilities to equity to assess the business's dependence on borrowed capital. By analyzing the total debt-to-equity ratio, an investor determines the stability of Viracta Therapeutics (VIRX), where the transparency of its targeted therapy strategy and proficient dialogue with the FDA minimize the risks of over-leverage during the scaling of development.

Analisis pesaing Viracta Therapeutics

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Rasio Total Utang marang Ekuitas CSBR (Champions Oncology)|Utang marang Ekuitas XBIT (xbiotech.com)|Total Utang marang Modal CVM (CEL-SCI)|Koefisien Total Utang marang Modal OS Therapies Inc. (OSTX)|RADX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ARTV (Artiva Biotherapeutics, Inc.)|ANL: Total Utang marang Modal|verupharma.com (VERU) - Total Utang marang Modal|TPST (Tempest Therapeutics, Inc.) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Xilio (XLO)|Rasio Total Utang marang Ekuitas RENB (Renovaro Inc.)|Utang Agregat marang Modal MURA|Total Utang marang Modal KAPA (Kairos Pharma)|Total Utang marang Modal OnKure Therapeutics, Inc. OKUR|GDTC: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Rasio Total Utang marang Ekuitas|THAR: Utang Agregat marang Modal|ADVB (Advanced Biomed Inc.) - Total Utang marang Modal|GNPX: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal CLDI|SBFM - Utang marang Modal|Utang marang Ekuitas Xenetic Biosciences, Inc. XBIO|Rasio Kabeh Utang marang Dana Pribadi SLRX|Purple Biotech - Total Utang marang Modal|AONC - Total Utang marang Modal|BeiGene (BGNE) - Utang marang Ekuitas|Utang Agregat marang Ekuitas CKPT (Checkpoint Therapeutics Inc.)|ELEV (Elevation Oncology, Inc.) - Total Utang marang Modal|Utang marang Modal iCAD Corp ICAD|Rasio Total Utang marang Ekuitas IKNA (Ikena Oncology, Inc.)|Total Utang marang Modal notablelabs.com (NTBL)|MorphoSys - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal NAYA (NAYA Biosciences Inc)|Ascentage Pharma Group Ltd - Total Utang marang Modal